Z8S-31444-55225
3 vaccinations
3 coded responses
38 check-ins
3 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 983 / WA
- Registered
- 2021-04-23
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-04-23
Registered in v-safe
-
2021-04-23
Dose 1 — Pfizer-BioNTech
- 2021-04-23
- 2021-04-24
- 2021-04-25
- 2021-04-27
- 2021-04-28
- 2021-04-29
- 2021-04-30
- 2021-05-07
-
2021-05-14
Dose 2 — Pfizer-BioNTech
- 2021-05-14
-
2021-05-15
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
-
2021-05-16
Survey response — days 1–6 daily, dose 2MedDRA: Dyspnoea — Feeling: Good · Site: Pain · Fatigue or tiredness · Be unable to do your normal daily activitiesFree text: Easily Winded/Short of BreathMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-05-17
- 2021-05-18
- 2021-05-19
- 2021-05-21
- 2021-05-28
- 2021-06-04
- 2021-06-11
- 2021-06-18
-
2021-06-25
Survey response — day 42, dose 2MedDRA: Fatigue, Oversensing — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Sudden onset of exhaustion, noise sensitivity, easily winded. Nearly identical to symptoms experienced immediately after the second dose. Lasted approximately 36 hours.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-08-13
- 2021-11-12
-
2022-01-14
Dose 3 — Pfizer-BioNTech
- 2022-01-14
-
2022-01-15
Health check-in — days 1–6 daily, dose 3Feeling: Poor · Site: Pain · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness · Be unable to work or attend school, Be unable to do your normal daily activitiesAdult check-in
- 2022-01-16
- 2022-01-17
- 2022-01-18
- 2022-01-19
- 2022-01-20
- 2022-01-22
- 2022-01-28
- 2022-02-05
- 2022-02-11
- 2022-02-18
-
2022-02-25
Survey response — day 42, dose 3MedDRA: Dizziness, Fatigue, Nausea, Unevaluable event — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professionalFree text: Symptoms: Fatigue, light-headedness, nausea · Healthcare visit (other): Scheduled a doctor appointmentMedDRA releases: 2024-11 · check-in free text available
-
2022-02-25
Report sent to call center — day 42, dose 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare pr1 call case(s)
- 2022-03-01
- 2022-04-15
- 2022-07-15
- 2023-01-14
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-04-23 | Pfizer-BioNTech | |
| 2 | 2021-05-14 | Pfizer-BioNTech | |
| 3 | 2022-01-14 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-02-25 | Unsuccessful |
Free text
Release 8 — days 1–6 daily, dose 2
Systemic reaction (other): Easily Winded/Short of Breath
Release 9 — day 42, dose 2
Symptoms: Sudden onset of exhaustion, noise sensitivity, easily winded. Nearly identical to symptoms experienced immediately after the second dose. Lasted approximately 36 hours.
Release 11 — day 42, dose 3
Symptoms: Fatigue, light-headedness, nausea
Healthcare visit (other): Scheduled a doctor appointment
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Unevaluable event | · | · | ✓ |
| SD | Dizziness | · | · | ✓ |
| SD | Fatigue | ✓ | ✓ | ✓ |
| SD | Nausea | · | · | ✓ |
| SD | Oversensing | ✓ | ✓ | ✓ |
| SRO | Dyspnoea | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release